This article is more than 5 years old. Information may no longer be current.
Dermatologic developments highlight World AIDS Day
In recognition of World AIDS Day, Healio.com/Dermatology is highlighting reports of dermatologic research and development in HIV-positive patients.
Published research included findings showing that Botox was an effective, long-lasting treatment for HIV-positive patients with posterior cheek enlargement and that HIV-positive patients experienced a high prevalence of pruritus that significantly affected their quality of life:
Hyaluronic acid filler effective at treating HIV-associated facial lipoatrophy
Patients with HIV-associated facial lipoatrophy who received treatment with hyaluronic acid filler achieved significant improvement in facial volume up to 1 year, with no permanent adverse events, according to study results published in JAMA Dermatology.
Researchers conducted an open-label study of 20 men (mean age, 57 years) with HIV-associated facial lipoatrophy who received one hyaluronic acid treatment with an optional touch-up at the Sacramento Veterans Medical Center, Mather, California. Read more
Botox effective in treating posterior cheek enlargement in HIV-positive patients
Botox was found to be an effective, long-lasting treatment for HIV-positive patients with posterior cheek enlargement, according to published results of a pilot study.
“Posterior cheek swelling is a characteristic and stigmatizing finding in some HIV-positive individuals,” researcher Alastair Carruthers, MD, FRCPC, told Healio.com/Dermatology. “It can be significantly reduced by injecting botulinum toxin A into the area.” Read more
VIDEO: Dermatologist discusses HIV and HPV-related conditions
WASHINGTON — In a video perspective from the American Academy of Dermatology Annual Meeting, Carrie Kovarik, MD, FAAD, discusses HIV and HPV-related conditions.
Kovarik, an associate professor of dermatology, dermatopathology and infectious disease at the University of Pennsylvania, said that she is seeing HPV-related malignancies, including squamous cell carcinoma, in her patients that HIV. Read more
AAD plenary session includes genetics, itch, skin cancer and HIV/AIDS
WASHINGTON — A wide range of topics, including chronic itch, genetics related to skin diseases, identification of a skin oncogene and the possible end of the HIV/AIDS pandemic, were presented at the plenary session at the American Academy of Dermatology Annual Meeting.
Anthony S. Fauci, MD, director of the National Institute of Allergy and Infectious Disease at the NIH, talked about “Ending the HIV/AIDS Pandemic: An Achievable Goal.”
He said it was appropriate to report his findings to a group of dermatologists because more than 90% of individuals with HIV/AIDS had some form of dermatological disease. Read more
Pruritus affected HIV-positive patients' quality of life
HIV-positive patients at a U.S. clinic experienced a high prevalence of pruritus that significantly affected their quality of life, according to recent study results.
Gil Yosipovitch, MD, department of dermatology and the Temple Itch Center, Temple University School of Medicine, and colleagues asked 201 HIV-positive patients (mean age, 47 years; 61% men) to complete a sociodemographic form and two itch questionnaires between August and December 2012 at an HIV outpatient clinic at the Wake Forest School of Medicine, Winston-Salem, N.C. Read more
Teledermatology potentially feasible for patients with HIV in remote areas
Researchers from the University of Pennsylvania suggest that mobile technology to practice teledermatology is feasible for patients with HIV in Botswana.
“In many parts of the world, particularly in sub-Saharan Africa, there is a severe shortage of dermatologic specialists,” the researchers wrote in JAMA Dermatology. “In these regions, this shortage is felt more acutely in communities with high rates of HIV, since there is an increased burden of both prevalence and severity of skin and mucosal disease in this group.” Read more